Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis

Quick facts

Author

Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska, Miloš Holánek, Roman Dubiański, Lenka Rušinová, Małgorzata Pieniążek, Anika Pękala ref

Published

2026 ref

Publisher

Tech Science Press ref

Journal

Oncology Research ref

DOI

10.32604/or.2026.089591 ref

Questions

Who wrote Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis?

Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis was written by Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska, Miloš Holánek.

When was Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis first published?

Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis was first published in 2026.

Sources

1. Publisher record (DOI, via Crossref)

Last updated 10 November 2026 · facts checked 10 November 2026

Cite this page

"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis". DigiNepal. Last updated 10 November 2026. https://diginpl.com/books/paper-or-2026-089591. Retrieved 14 November 2026.

Machine-readable versions: JSON · Markdown